CA1187413A - High titer production of hepatitis a virus background of the invention - Google Patents

High titer production of hepatitis a virus background of the invention

Info

Publication number
CA1187413A
CA1187413A CA000381716A CA381716A CA1187413A CA 1187413 A CA1187413 A CA 1187413A CA 000381716 A CA000381716 A CA 000381716A CA 381716 A CA381716 A CA 381716A CA 1187413 A CA1187413 A CA 1187413A
Authority
CA
Canada
Prior art keywords
growth stage
purine
cell culture
hav
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000381716A
Other languages
English (en)
French (fr)
Inventor
William J. Mcaleer
Henry Z. Markus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of CA1187413A publication Critical patent/CA1187413A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA000381716A 1980-07-23 1981-07-14 High titer production of hepatitis a virus background of the invention Expired CA1187413A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US171,621 1980-07-23
US06/171,621 US4301249A (en) 1980-07-23 1980-07-23 High titer production of hepatitis A virus

Publications (1)

Publication Number Publication Date
CA1187413A true CA1187413A (en) 1985-05-21

Family

ID=22624494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000381716A Expired CA1187413A (en) 1980-07-23 1981-07-14 High titer production of hepatitis a virus background of the invention

Country Status (11)

Country Link
US (1) US4301249A (https=)
EP (1) EP0044793B1 (https=)
JP (1) JPS5753410A (https=)
AT (1) ATE20250T1 (https=)
CA (1) CA1187413A (https=)
DE (1) DE3174765D1 (https=)
DK (1) DK326781A (https=)
ES (1) ES504199A0 (https=)
GR (1) GR74594B (https=)
IE (1) IE51454B1 (https=)
PT (1) PT73371B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
DE3633550A1 (de) * 1986-10-02 1988-04-14 Behringwerke Ag Vaccine gegen hepatitis a
US5268292A (en) * 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US6872549B2 (en) * 2002-03-27 2005-03-29 Immunex Corporation Methods for increasing polypeptide production
WO2008038641A1 (en) * 2006-09-26 2008-04-03 Kyoto University Method of proliferating hepatitis virus, hollow fiber for culturing hepatitis virus-infected cells and utilization of the same
JP5352578B2 (ja) * 2007-05-04 2013-11-27 バクスター・インターナショナル・インコーポレイテッド ウイルスの増殖のための二段階温度プロフィール
JP5692688B2 (ja) * 2008-06-26 2015-04-01 東洋紡株式会社 感染性ｃ型肝炎ウイルス粒子の製造方法、およびその利用
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615024A (en) * 1968-08-26 1971-10-26 Amicon Corp High flow membrane
US3883393A (en) * 1972-05-18 1975-05-13 Us Health Education & Welfare Cell culture on semi-permeable tubular membranes
US3821087A (en) * 1972-05-18 1974-06-28 Dedrick R Cell culture on semi-permeable tubular membranes
US3997396A (en) * 1973-07-02 1976-12-14 Monsanto Company Method for the in vitro propagation and maintenance of cells
US4087327A (en) * 1976-04-12 1978-05-02 Monsanto Company Mammalion cell culture process
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4301250A (en) * 1979-11-02 1981-11-17 Merck & Co., Inc. Method of producing hepatitis B surface antigen

Also Published As

Publication number Publication date
GR74594B (https=) 1984-06-29
IE811655L (en) 1982-01-23
ES8205016A1 (es) 1982-05-16
US4301249A (en) 1981-11-17
ATE20250T1 (de) 1986-06-15
DK326781A (da) 1982-01-24
EP0044793B1 (en) 1986-06-04
PT73371A (en) 1981-08-01
ES504199A0 (es) 1982-05-16
IE51454B1 (en) 1986-12-24
EP0044793A2 (en) 1982-01-27
DE3174765D1 (en) 1986-07-10
EP0044793A3 (en) 1983-01-05
JPS5753410A (en) 1982-03-30
PT73371B (en) 1983-06-15

Similar Documents

Publication Publication Date Title
CA1187413A (en) High titer production of hepatitis a virus background of the invention
CA1175745A (en) Methods of producing hb sag
RU2314344C2 (ru) Способ крупномасштабного производства вирусного антигена
KR100968141B1 (ko) 세포 배양물에서 바이러스의 증식 방법
CN103952376A (zh) 培养细胞、增殖和纯化病毒的方法
CN101979519A (zh) 一种制备伪狂犬病疫苗的方法
JPH0748277A (ja) Ａ型肝炎ウィルスワクチン
CN106676076A (zh) 一种无血清Vero细胞制备轮状病毒疫苗原液的方法以及无血清轮状病毒疫苗制品
CN1970080A (zh) 用悬浮的Vero细胞生产病毒疫苗的方法
US4301250A (en) Method of producing hepatitis B surface antigen
CN100374552C (zh) 大规模生产甲型肝炎病毒的方法
JP2633391B2 (ja) 付着的に結合した細胞を有するマトリックスおよびウイルス／ウイルス抗原の製造方法
US5719051A (en) Perfusion system and a method for the large scale production of virus or virus antigen
Nicholson Growth of fish cell lines on microcarriers
Nilsson et al. [35] Entrapment of animal cells
CN111662881B (zh) 新型冠状病毒Vero细胞灭活疫苗病毒液及其生产方法
CN1617882A (zh) 从链霉蛋白酶中分离和纯化胰蛋白酶的方法及其用途
Choi et al. High cell density perfusion cultures of anchorage-dependent Vero cells in a depth filter perfusion system
SU1317021A1 (ru) Штамм диплоидных клеток кожи и мышц эмбриона человека,используемый дл культивировани вирусов
Johnson et al. Production of Venezuelan equine encephalitis virus in cells grown on artificial capillaries
Thomson et al. Growth of rubella virus in a glass bead propagator
SU764391A1 (ru) Способ культивировани вирусов
RU1806190C (ru) Штамм VIRUS нератIтIS А номINIS дл приготовлени вакцинных и диагностических препаратов
Looby et al. The production of influenza virus by immobilised MDCK cells
WO1995004812A1 (en) Hepatitis a virus culture process

Legal Events

Date Code Title Description
MKEX Expiry